Paraquat Lawsuit Advertising: $711 CPAs, Settlement Framework Signed, and Syngenta Just Quit

$711 per signed retainer. Down from $6,000 three years ago. And the defendants just announced they’re stopping production.

Paraquat is a tort in its final chapter. The settlement framework is signed. Syngenta is shutting down its only production facility. Every case that’s ever been set for trial settled before a jury heard the evidence.

6,500 cases pending. The numbers are declining because settlements are absorbing inventory. The acquisition window is closing.

The Settlement Signal

Syngenta has never let a paraquat case reach a jury verdict. Not once.

January 26, 2026. The Mertens bellwether trial in Philadelphia. Retired landscaper, age 77, decades of paraquat exposure, Parkinson’s diagnosis. The case was set. Jury selection day arrived.

Syngenta settled on the courthouse steps. Confidential terms.

That’s not new behavior. In 2017, Syngenta quietly settled seven Illinois state court cases for $187.5 million. The details stayed sealed for years. That’s $26.8 million per plaintiff.

You don’t settle bellwether cases the day before jury selection unless you’re paying a premium. You don’t pay $187.5 million for seven cases unless you know what a jury would do with the evidence.

The MDL

MDL-3004 sits in the Southern District of Illinois under Chief Judge Nancy Rosenstengel. Created June 2021. Over 8,257 total cases filed, with roughly 6,500 still pending.

The case count is declining. Not because filing slowed. Because settlements started absorbing inventory. In November 2025 alone, 499 cases resolved.

A tentative settlement framework was announced April 2025. Reportedly signed August 2025. The judge has stayed case deadlines repeatedly to let finalization proceed. A lien resolution administrator was appointed in February 2026.

That appointment is the tell. You don’t appoint a lien administrator unless money is about to move.

State court cases continue independently. Philadelphia has 1,600+ pending. State courts have consistently produced higher per-case values than the MDL in this tort.

The Science

The science linking paraquat to Parkinson’s disease isn’t subtle. It’s the same mechanism that makes the herbicide toxic to plants: oxidative stress that kills cells. In humans, it destroys dopaminergic neurons. That’s Parkinson’s.

Tanner et al. (2011) in Environmental Health Perspectives found paraquat users were 2.5 times more likely to develop Parkinson’s disease. A meta-analysis of 13 studies found 64% increased risk. Other research puts the number at 250%.

The dose-response relationship is established. More exposure, more risk. Living within 500 feet of treated farmland increases risk by 75%.

The Guardian revealed in June 2023 that internal Syngenta documents showed the company knew about the link for decades. They pursued what internal memos described as a strategy to “diffuse the potential threats” and “influence future work by external researchers.”

They knew. They buried it. The documents are in discovery.

The Daubert Setback and Recovery

April 2024 was a bad month. Judge Rosenstengel excluded the testimony of plaintiffs’ key causation expert, Dr. Martin Wells, on Daubert grounds. Four bellwether cases were dismissed.

The plaintiffs rebuilt. New experts. New case selections. Ten replacement cases entered discovery by August 2024. The litigation didn’t die. It pivoted.

The EPA hasn’t helped plaintiffs. Their 2024 review controversially concluded the “weight of evidence is not sufficient to link paraquat exposure to Parkinson’s disease.” The Environmental Working Group identified five fatal flaws in the EPA’s analysis. The Michael J. Fox Foundation submitted over 90 scientific studies challenging the finding.

In January 2026, EPA Administrator Lee Zeldin announced manufacturers must prove paraquat is safe under real-world conditions. The regulatory tide is turning.

Syngenta Quits

March 3, 2026. Syngenta announced it will shut down its only paraquat production facility in Huddersfield, UK, by end of June.

That’s not an admission. Companies never say it’s an admission. But you don’t close your production line for a product you believe is safe.

Here’s the irony. Syngenta is owned by Sinochem, a Chinese state-owned enterprise. China banned paraquat domestically in 2016. But kept manufacturing it for export to the US. For a decade.

The production shutdown doesn’t end US sales immediately. Other manufacturers can still produce and distribute. But the signal is unmistakable.

Over 60 countries have already banned paraquat. The EU banned it in 2007. State legislatures in Pennsylvania, Missouri, Vermont, and New York introduced new ban legislation in January 2026.

The Lead Economics

Lead costs collapsed. That’s the opportunity.

At peak (2022), signed retainers ran $4,000-$6,000. TV was the primary channel. Paraquat ads aired every six minutes nationally. $812,000 in two months.

Now: $320 per raw lead. $711 per signed retainer. The market corrected hard.

Whitehardt ranks paraquat #5 at 8.8. Meta is maxed at 5.0. PPC at 1.0. TV at zero. The channel mix flipped entirely from broadcast to digital.

Why? The settlement framework. When defendants signal resolution, risk drops, confidence rises, and lead costs follow. Firms can acquire at $711 knowing the settlement math on the other side.

Projected settlements: $100,000-$150,000 at the low end. $400,000-$1,000,000+ for severe Parkinson’s with documented occupational exposure. Average projections from plaintiff attorneys: $600,000-$900,000 per viable case.

The MOIC on a $711 CPA against a $600,000 settlement is 844:1. Even at the conservative floor, $100,000 on a $711 lead, that’s 141:1. The economics are among the best in active mass tort.

Who’s Being Sued

Two defendants. Both running out of runway.

Syngenta is the primary target. Swiss agrochemical company, Chinese state-owned parent. Manufacturer of Gramoxone and other paraquat products. They knew about the Parkinson’s link for decades. The internal documents prove it. They’re shutting down production.

Chevron distributed paraquat in the US from 1964 to 1986. They started the American supply chain. Twenty-two years of distribution liability.

Neither defendant has ever allowed a jury to hear paraquat evidence. The settlement pattern speaks louder than any press release.

The Advertising Playbook

Zero TV spend. The entire tort runs on Meta.

That’s unusual for a #5 hot tort. Most torts at this ranking have significant broadcast presence. Paraquat doesn’t, for two reasons.

First, the plaintiff demographic is narrow. Occupational paraquat applicators. Farmworkers. Pesticide handlers. Landscapers. You don’t find them watching daytime TV.

Second, the settlement framework made digital more efficient. When the case economics are clear, Meta targeting with intent-based creative outperforms the broadcast shotgun.

CTV is the open lane at roughly 10%. Agricultural workers and rural communities over-index on ad-supported streaming. Tubi, Pluto, Roku. Household-level targeting by geography (agricultural DMAs) and occupation interests gets you closer to the plaintiff pool than any other channel.

Search captures 30%. “Paraquat lawsuit” and “paraquat Parkinson’s” keywords drive high-intent leads. The searchers already know they were exposed. Conversion is strong.

Qualification Criteria

Paraquat has the strictest qualification criteria of any active mass tort. This isn’t a broad-exposure tort. It’s occupational.

Diagnosed with Parkinson’s disease between ages 40-60. Directly exposed to paraquat: mixed, applied, transferred, or worked in a production facility. Exposure after 1963.

Must have held a Certified Pesticide Applicator License or worked under someone who did. Must have been a W-2 worker. Brand-name paraquat products only. No generics.

No residential-only use. No drift cases. No deceased cases. Must be prescribed Parkinson’s disease medications by a neurologist.

The screening bar is brutal. Most inquiries fail at “did you directly handle paraquat.” Drift exposure, residential proximity, and consumer use don’t qualify. That’s why the CPA is $711 and not $200.

The Play

Paraquat is in the closing window. Three things to watch.

First, the settlement. The framework is signed. The lien administrator is appointed. When the deal finalizes, new case filing stops or becomes significantly harder. Firms acquiring now are buying into a known resolution pathway.

Second, the CPA floor. At $711, paraquat leads are cheaper than any other top-5 hot tort. The settlement certainty pushed prices down. If the deal closes and CPAs stay low until the last filing date, the current buyers get the best economics the tort has ever offered.

Third, Syngenta’s production shutdown. It doesn’t end the litigation. But it ends the argument that paraquat is safe. You don’t close a factory for a product you’re willing to defend in court.

The firms that win paraquat aren’t the firms running the most creative Meta campaigns. They’re the ones who’ve been quietly building portfolios of occupational exposure cases with documented Parkinson’s diagnoses and proper licensing records. Because when the settlement grid drops, those are the cases that get paid first.

References

1. In Re: Paraquat Products Liability Litigation, MDL No. 3004, S.D. Illinois
2. Tanner CM, et al. Rotenone, Paraquat, and Parkinson's Disease. Environmental Health Perspectives. 2011;119(6):866-872
3. Whitehardt Mass Tort Report: Hot Tort Rankings and Lead Economics, Q1 2026
4. The Guardian. Syngenta knew about paraquat-Parkinson's link for decades, internal documents show. June 2023
5. Michael J. Fox Foundation. What Syngenta's Decision to End Paraquat Production Means for Parkinson's Risk. March 2026